NA
CLDI icon

NewEdge Advisors’s Calidi Biotherapeutics CLDI Stock Holding History

NewEdge Advisors’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-917
Closed -$6.23K – 4011
2025
Q1 		$6.23K Buy
+917
New +$10.5K ﹤0.01% 3239

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's CLDI Position: Q2 2025 in Review

NewEdge Advisors sold out of Calidi Biotherapeutics (CLDI) in Q2 2025, closing a stake of 917 shares — an estimated $6.23K sold.

NewEdge Advisors first reported a position in CLDI in Q1 2025 and held it in 1 quarter. The position peaked at $6.23K in Q1 2025. 35 funds tracked by Wall St. Rank hold CLDI as of Q2 2025.

  • NewEdge Advisors reported no remaining Calidi Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • NewEdge Advisors sold 917 Calidi Biotherapeutics shares in Q2 2025, an estimated $6.23K.
  • NewEdge Advisors first reported a position in Calidi Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • NewEdge Advisors's Calidi Biotherapeutics position peaked at $6.23K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.